Doença rara caracterizada por fraqueza muscular progressiva, podendo apresentar bolhas intraepidérmicas, atrofia da língua e obstrução das vias aéreas. Afeta também o coração com fibrose e extrassístoles ventriculares, além de neuropatia periférica e contraturas.
Introdução
O que você precisa saber de cara
Visão geral
Sinais e sintomas
As manifestações clínicas relatadas incluem fraqueza muscular, astenia, fraqueza do músculo fibular e fraqueza muscular do membro inferior, associadas a amiotrofia do membro inferior, amiotrofia peitoral, contratura do cotovelo, anormalidade do músculo masseter, atrofia da língua e substituição gordurosa do músculo esquelético. Podem ocorrer também alterações articulares e cutâneas, como camptodactilia do dedo, bolhas intraepidérmicas e pápulas.[1][2]
O quadro pode abranger envolvimento cardíaco e respiratório, manifestado por função ventricular esquerda anormal, fibrose cardíaca intersticial, extrassístoles ventriculares, onda P ausente e obstrução das vias aéreas. Foram descritos ainda neuropatia periférica, pernas inquietas, oftalmoplegia externa parcial restritiva e comprometimento da cognição construtiva visuoespacial. No plano laboratorial e histopatológico, observa-se creatina quinase altamente elevada, concentração elevada de creatina circulante e alfa-distroglicano reduzido na fibra muscular.[1][2]
Causas genéticas
A condição está associada a variantes em múltiplos genes, incluindo CRPPA (D-ribitol-5-phosphate cytidylyltransferase), TNPO3 (Transportin-3), FKTN (Ribitol-5-phosphate transferase FKTN), POMT2 (Protein O-mannosyl-transferase 2), POMGNT1 (Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1) e JAG2 (Protein jagged-2).[1][3]
Também constam alterações nos genes SGCB (Beta-sarcoglycan), LRP12 (Low-density lipoprotein receptor-related protein 12), MYH7 (Myosin-7), SYNE1 (Nesprin-1), MYOT (Myotilin) e TRIM32 (E3 ubiquitin-protein ligase TRIM32).[1][3]
Diagnóstico
Tratamentos citados na literatura
A literatura científica apresenta associações mineradas por processamento automatizado com termos e substâncias biomédicas, não constituindo recomendação de uso clínico. Os compostos mais frequentemente citados incluem: Oligonucleotides Antisense (195 publicações), Steroids (172 publicações), Calcium (150 publicações), Prednisone (133 publicações), deflazacort (106 publicações), Oligonucleotides (97 publicações), eteplirsen (95 publicações), Morpholinos (82 publicações), Prednisolone (73 publicações) e ataluren (62 publicações).[4]
Conteúdo informativo gerado e mantido automaticamente a partir de fontes oficiais (Orphanet, HPO, OMIM, SUS). Não substitui avaliação médica.
A **distrofia muscular progressiva** é um grupo de condições raras que compromete a função dos tecidos musculares ao longo do tempo. As famílias costumam notar sintomas como fraqueza muscular nas pernas, amiotrofia e cansaço físico acentuado. No Brasil, a condição não consta na lista oficial de Protocolos Clínicos e Diretrizes Terapêuticas (PCDT) de doenças raras do Ministério da Saúde. Por não haver medicamentos federais dispensados específicos nesta categoria, o atendimento clínico de suporte é conduzido pela rede pública do SUS.
Doença rara caracterizada por fraqueza muscular progressiva, podendo apresentar bolhas intraepidérmicas, atrofia da língua e obstrução das vias aéreas. Afeta também o coração com fibrose e extrassístoles ventriculares, além de neuropatia periférica e contraturas.
O que está sendo pesquisado
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 239 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 657 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
57 genes identificados com associação a esta condição.
Curadoria gene-doença
fontes oficiaisMuscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Muscular dystrophy, limb-girdle, autosomal dominant 2
An autosomal dominant myopathy characterized by proximal muscle weakness primarily affecting the lower limbs, but also affecting the upper limbs in most patients. Affected individuals also have distal muscle weakness of the hands and lower leg muscles. The disease has generally a benign clinical course but some individuals with childhood or juvenile onset manifest severe widespread myopathy, leading to wheelchair dependency and respiratory insufficiency. Muscle biopsy shows dystrophic changes with abnormal nuclei, rimmed vacuoles, and filamentous inclusions.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3
An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Muscular dystrophy, limb-girdle, autosomal recessive 27
An autosomal recessive muscular disorder characterized by progressive muscle weakness most prominent in the proximal lower limb and axial muscles, and resulting in walking difficulty or loss of ambulation. Additional more variable features include neck muscle weakness, scoliosis, and joint contractures. Some affected individuals manifest impaired intellectual development or speech delay, cardiomyopathy, and cardiac arrhythmia. Muscle biopsy shows non-specific dystrophic changes.
Muscular dystrophy, limb-girdle, autosomal recessive 4
An autosomal recessive degenerative myopathy characterized by pelvic and shoulder muscle wasting, onset usually in childhood and variable progression rate.
Oculopharyngodistal myopathy 1
A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM1 inheritance pattern is autosomal dominant.
Cardiomyopathy, familial hypertrophic, 1
A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Spinocerebellar ataxia, autosomal recessive, 8
A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR8 is an autosomal recessive form.
Myopathy, myofibrillar, 3
A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM3 is characterized by progressive skeletal muscle weakness greater distally than proximally, tight heel cords, hyporeflexia, cardiomyopathy and peripheral neuropathy in some patients. Affected muscle exhibits disorganization and streaming of the Z-line, presence of large hyaline structures, excessive accumulation of myotilin and other ectopically expressed proteins and prominent congophilic deposits.
Muscular dystrophy, limb-girdle, autosomal recessive 8
An autosomal recessive degenerative myopathy characterized by pelvic girdle, shoulder girdle and quadriceps muscle weakness. Clinical phenotype and severity are highly variable. Disease progression is slow and most patients remain ambulatory into the sixth decade of life.
Epidermolysis bullosa simplex 5C, with pyloric atresia
A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma. EBS5C is an autosomal recessive disorder characterized by severe skin blistering at birth and congenital pyloric atresia. Death usually occurs in infancy.
Arrhythmogenic right ventricular dysplasia, familial, 5
A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.
Cardiomyopathy, familial hypertrophic, 25
A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
Fibrosis of extraocular muscles, congenital, 1
A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Patients affected by congenital fibrosis of extraocular muscles type 1 show an absence of the superior division of the oculomotor nerve (cranial nerve III) and corresponding oculomotor subnuclei.
Fibrosis of extraocular muscles, congenital, 3A
A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 3 presents as a non-progressive, autosomal dominant disorder with variable expression. Patients may be bilaterally or unilaterally affected, and their oculo-motility defects range from complete ophthalmoplegia (with the eyes fixed in a hypo- and exotropic position), to mild asymptomatic restrictions of ocular movement. Ptosis, refractive error, amblyopia, and compensatory head positions are associated with the more severe forms of the disorder. In some cases, the ocular phenotype is accompanied by additional features including developmental delay, corpus callosum agenesis, basal ganglia dysmorphism, facial weakness, polyneuropathy.
Myopathy, autosomal recessive, with rigid spine and distal joint contractures
An autosomal recessive degenerative myopathy characterized by muscle weakness initially involving the proximal lower limbs, followed by distal upper and lower limb muscle weakness and atrophy. Other features include joint contractures, rigid spine, and restricted pulmonary function. Cardiac involvement has been observed in some patients. Disease onset is in the first or second decades of life.
Muscular dystrophy, limb-girdle, autosomal recessive 28
An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR28 is characterized by progressive muscle weakness affecting the proximal and axial muscles of the upper and lower limbs, and highly variable age at onset. Most patients have limited ambulation or become wheelchair-bound within a few decades, and respiratory insufficiency commonly occurs.
Oculopharyngodistal myopathy 4
A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM4 is an autosomal dominant form characterized by slow progression and onset of symptoms in the second or third decades.
Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.
Emery-Dreifuss muscular dystrophy 6, X-linked
A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Fibrosis of extraocular muscles, congenital, 2
A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 2 may result from the defective development of the oculomotor (nIII), trochlear (nIV) and abducens (nVI) cranial nerve nuclei.
Muscular dystrophy, limb-girdle, autosomal dominant 3
An autosomal dominant degenerative myopathy characterized by slowly progressive wasting and weakness of the proximal muscles of arms and legs around the pelvic or shoulder girdles, elevated creatine kinase levels and dystrophic features on muscle biopsy. LGMDD3 is characterized by a mild late-onset and is associated with progressive fingers and toes flexion limitation. Affected individuals may also develop cataracts before age 50.
Dowling-Degos disease 4
A form of Dowling-Degos disease, a genodermatosis manifesting with postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. DDD4 is characterized by prominent involvement of non-flexural skin areas.
Muscular dystrophy, limb-girdle, autosomal recessive 25
An autosomal recessive muscular disorder characterized by slowly progressive onset of proximal lower limb weakness in adulthood, syncopal episodes, and markedly increased serum creatine kinase, which can increase further after strenuous exercise.
Muscular dystrophy, limb-girdle, autosomal recessive 26
An autosomal recessive muscular disorder characterized by adult onset of weakness and atrophy of proximal limb muscles, elevated serum creatine kinase levels, and dystrophic findings on muscle biopsy. There is no cardiac or respiratory involvement.
Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2
An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.
Oculopharyngeal muscular dystrophy 1
An autosomal dominant, late-onset, slowly progressive myopathy characterized by eyelid ptosis, dysphagia and, sometimes by other cranial and limb-muscle involvement.
Muscular dystrophy, limb-girdle, autosomal recessive 3
An autosomal recessive degenerative myopathy characterized by progressive muscle wasting from early childhood with loss of independent ambulation by teenage years. Muscle biopsy shows necrosis, decreased immunostaining for alpha sarcoglycan, and adhalin deficiency.
Muscular dystrophy, limb-girdle, autosomal recessive 6
An autosomal recessive degenerative myopathy initially affecting the proximal limb girdle musculature. Muscle from patients shows a complete loss of delta-sarcoglycan as well as of the others components of the sarcoglycan complex.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.
Neuronal intranuclear inclusion disease
An autosomal dominant, slowly progressive, neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in the central and peripheral nervous system, and also in the visceral organs. Clinical manifestations are variable and include pyramidal and extrapyramidal symptoms, cerebellar ataxia, cognitive decline and dementia, peripheral neuropathy, and autonomic dysfunction.
Emery-Dreifuss muscular dystrophy 2, autosomal dominant
A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
Muscular dystrophy, limb-girdle, autosomal recessive 29
An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR29 is characterized by muscle weakness predominantly affecting the proximal lower limbs, although upper limb involvement also occurs. Additional features include joint contractures, spinal abnormalities, and significant restrictive ventilatory dysfunction. In rare cases, central nervous system involvement has been reported, including cataracts, developmental delay, and brain imaging abnormalities.
Emery-Dreifuss muscular dystrophy 1, X-linked
A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
Oculopharyngodistal myopathy 2
A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM2 inheritance pattern is autosomal dominant.
Muscular dystrophy, limb-girdle, autosomal recessive 18
A form of limb-girdle muscular dystrophy characterized by proximal muscle weakness with childhood onset, resulting in gait abnormalities and scapular winging. Serum creatine kinase is increased. A subset of patients may show a hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay.
Muscular dystrophy, limb-girdle, autosomal recessive 5
An autosomal recessive degenerative myopathy characterized by rapidly progressive muscle wasting from early childhood with loss of independent ambulation around age 12 years, dystrophic pattern on muscle biopsy, absence of gamma-sarcoglycan and normal dystrophin immunostaining.
Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8
An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.
Merosin-deficient congenital muscular dystrophy 1A
Characterized by difficulty walking, hypotonia, proximal weakness, hyporeflexia, and white matter hypodensity on MRI.
Myopathy, myofibrillar, 9, with early respiratory failure
An autosomal dominant myopathy characterized by adulthood onset of weakness in proximal, distal, axial and respiratory muscles. Pelvic girdle weakness, foot drop and neck weakness are the main symptoms at onset, but ultimately the weakness usually involves the proximal compartment of both upper and lower limbs. Additional features include variable degrees of Achilles tendon contractures, spinal rigidity and muscle hypertrophy. Respiratory involvement often leads to requirement for non-invasive ventilation support.
Dystrophia myotonica 2
A multisystem disease characterized by the association of proximal muscle weakness with myotonia, cardiac manifestations and cataract. Additional features can include hyperhidrosis, testicular atrophy, insulin resistance and diabetes and central nervous system anomalies in rare cases.
Ullrich congenital muscular dystrophy 2
A form of Ullrich congenital muscular dystrophy, a disease characterized by generalized muscle weakness and striking hypermobility of distal joints in conjunction with variable contractures of more proximal joints and normal intelligence. Additional findings may include kyphoscoliosis, protruded calcanei, and follicular hyperkeratosis (rough skin). More severely affected patients manifest at birth and never achieve independent ambulation, while patients with milder phenotypes might maintain ambulation into adulthood. UCMD2 is a severe, autosomal recessive form with onset at birth.
Congenital bile acid synthesis defect 5
An autosomal recessive disorder characterized by hepatosplenomegaly, hepatic fibrosis, progressive liver failure, and accumulation of peroxisomal C27-bile acid intermediates in plasma.
Fibrosis of extraocular muscles, congenital, 5
An ocular motility disorder characterized by congenital dysinnervation of various cranial nerves to ocular muscles. Clinical features are ophthalmoplegia, anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head.
Bethlem myopathy 1C
A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. BTHLM1C inheritance is autosomal dominant.
Immunodeficiency-centromeric instability-facial anomalies syndrome 1
A rare disorder characterized by a variable immunodeficiency resulting in recurrent infections, facial anomalies, and branching of chromosomes 1, 9, and 16. Other variable symptoms include growth retardation, failure to thrive, and psychomotor retardation. Laboratory studies show limited hypomethylation of DNA in a small fraction of the genome in some, but not all, patients.
Bethlem myopathy 1A
A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.
Bethlem myopathy 1B
A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.
Muscular dystrophy, limb-girdle, autosomal recessive 1
An autosomal recessive degenerative myopathy characterized by progressive symmetrical atrophy and weakness of the proximal limb muscles and elevated serum creatine kinase. The symptoms usually begin during the first two decades of life, and the disease gradually worsens, often resulting in loss of walking ability 10 or 20 years after onset.
Duchenne muscular dystrophy
Most common form of muscular dystrophy; a sex-linked recessive disorder. It typically presents in boys aged 3 to 7 year as proximal muscle weakness causing waddling gait, toe-walking, lordosis, frequent falls, and difficulty in standing up and climbing up stairs. The pelvic girdle is affected first, then the shoulder girdle. Progression is steady and most patients are confined to a wheelchair by age of 10 or 12. Flexion contractures and scoliosis ultimately occur. About 50% of patients have a lower IQ than their genetic expectations would suggest. There is no treatment.
Muscular dystrophy, limb-girdle, autosomal recessive 2
An autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.
Gnathodiaphyseal dysplasia
Rare skeletal syndrome characterized by bone fragility, sclerosis of tubular bones, and cemento-osseous lesions of the jawbone. Patients experience frequent bone fractures caused by trivial accidents in childhood; however the fractures heal normally without bone deformity. The jaw lesions replace the tooth-bearing segments of the maxilla and mandible with fibrous connective tissues, including various amounts of cementum-like calcified mass, sometimes causing facial deformities. Patients also have a propensity for jaw infection and often suffer from purulent osteomyelitis-like symptoms, such as swelling of and pus discharge from the gums, mobility of the teeth, insufficient healing after tooth extraction and exposure of the lesions into the oral cavity.
Muscular dystrophy-dystroglycanopathy limb-girdle C9
An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.
Dystrophia myotonica 1
A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.
Medicamentos e terapias
Mecanismo: Sodium channel alpha subunit blocker
Mecanismo: Glucocorticoid receptor agonist
Mecanismo: Glycogen synthase kinase-3 beta inhibitor
Mecanismo: Growth/differentiation factor 8 inhibitor
Variantes genéticas (ClinVar)
555 variantes patogênicas registradas no ClinVar.
Classificação de variantes (ClinVar)
Distribuição de 13 variantes classificadas pelo ClinVar.
Vias biológicas (Reactome)
122 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Distrofia muscular progressiva
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
Muscle meets Lysosomes: emerging strategies in muscular dystrophy.
Duchenne muscular dystrophy (DMD) is caused by the loss of DMD (dystrophin), leading to sarcolemmal fragility and progressive muscle degeneration. Although adeno-associated viral (AAV) microdystrophin (µDMD) therapies have advanced clinically, their benefits remain partial, highlighting the need to identify secondary cellular defects that limit therapeutic efficacy. In our recent study, we demonstrated that lysosomal dysfunction is a conserved, intrinsic, and persistent feature of DMD pathology. Using mouse, canine, and human dystrophic muscle, we show marked lysosomal membrane permeabilization (LMP), impaired acidification, defective proteolysis, and inefficient membrane repair, all hallmarks of compromised lysosomal integrity. Cholesterol accumulation within dystrophic myofibers further exacerbates these defects, linking lipid dysregulation to lysosomal injury and accelerated muscle degeneration. We find macroautophagy/autophagy impairment in DMD stems in part from reduced autophagosome-lysosome fusion, reframing autophagy failure as a downstream consequence of lysosomal damage. µDMD gene therapy only partially corrects these abnormalities and does not fully restore lysosomal stability. In contrast, combining µDMD with the lysosome-activating disaccharide trehalose produces synergistic benefits, improving muscle strength, architecture, and molecular signatures beyond either treatment alone. These findings position lysosomal dysfunction as a central driver of DMD pathophysiology and support therapeutic strategies that pair gene restoration with lysosomal enhancement.Abbreviation: AAV: adeno-associated virus; DAGC: DMD-associated glycoprotein complex; DMD: Duchenne muscular dystrophy; FDA: Food and Drug Administration; LMP: lysosome membrane permeabilization; MTOR: mechanistic target of rapamycin kinase; µDMD: microdystrophin.
A national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.
Rare diseases (RDs) collectively affect >400 million people worldwide, but fragmented infrastructure and biospecimen scarcity impede progress. China's heterogeneous healthcare landscape magnifies these challenges. Since 2016, Peking Union Medical College Hospital (PUMCH) RD Biobank has pioneered a scalable model integrating 446 institutions via national networks, and setup Quality Management System since 2019 with the ISO 20387:2018, that received accreditation in 2022. Our secure digital platform standardizes biospecimen protocols (acquisition/processing/storage) and enables ethical data/specimen sharing through auditable Material Transfer Agreements/Data Use Agreements. Among 49,759 enrolled patients, 73.13% were diagnosed, while 26.87% were undiagnosed, with pediatric cases (50.75%) and males (52.39%) predominating. Phenotypic analysis showed 78.51% single-system versus 21.20% multisystem involvement. Top diagnoses included congenital scoliosis and progressive muscular dystrophy. Specimen diversity revealed system-specific patterns: musculoskeletal/nervous/sensory systems linked to multiple specimen types; immune/genitourinary to fluids; cardiovascular/neoplastic to derivatives; endocrine uniquely to tissues. Nucleic acids (93.4%) and blood specimens (21.4%) formed core resources, while induced pluripotent stem cells/organoids prioritized for cardiovascular/neoplastic RDs enable functional validation. This framework transcends biospecimen fragmentation by uniting clinical, molecular, and institutional dimensions. It demonstrates how centralized governance and interoperable systems can accelerate RD research globally. By transforming isolated data into collaborative discovery engines, we provide a blueprint for converting RD challenges into precision diagnostics and therapies, which are urgently needed for the millions of individuals worldwide who remain undiagnosed. Emery-Dreifuss muscular dystrophy (EDMD) is characterized by the clinical triad of joint contractures that begin in early childhood; slowly progressive muscle weakness and wasting initially in a humeroperoneal distribution that later extends to the scapular and pelvic girdle muscles; and cardiac involvement that may manifest as palpitations, presyncope and syncope, poor exercise tolerance, and congestive heart failure along with variable cardiac rhythm disturbances. Age of onset, severity, and progression of muscle and cardiac involvement demonstrate both inter- and intrafamilial variability. Clinical variability ranges from early onset with severe presentation in childhood to late onset with slow progression in adulthood. In general, joint contractures appear during the first two decades, followed by muscle weakness and wasting. Cardiac involvement usually occurs after the second decade, and respiratory function may be impaired in some individuals. The clinical diagnosis of EDMD can be established in a proband with characteristic early and prominent joint contractures, humeroperoneal (or more rarely limb-girdle) muscle weakness and wasting, and later-onset cardiac disease. The molecular diagnosis is established in a proband with characteristic clinical findings and a hemizygous pathogenic variant in EMD or FHL1, a heterozygous pathogenic variant in LMNA, SUN2, SYNE1, SYNE2, or TMEM43, or (more rarely) biallelic pathogenic variants in LMNA or SUN1 identified by molecular genetic testing. Treatment of manifestations: Surgery to release contractures and manage scoliosis as needed; aids (canes, walkers, orthoses, wheelchairs) as needed to help ambulation; physical therapy and stretching to prevent contractures. Treatment for cardiac disease can include antiarrhythmic drugs, oral anticoagulation, ablation procedures, cardiac pacemaker, implantable cardioverter-defibrillator, pharmacologic and nonpharmacologic therapy for heart failure; heart transplantation for the end stages of heart failure as appropriate; respiratory aids (respiratory muscle training, assisted coughing techniques, mechanical ventilation) as needed; in those with associated metabolic features, treatment may include dietary modification, medications to improve hypertriglyceridemia and hypercholesterolemia, and diabetes / insulin resistance medications. Surveillance: Assess joints for contractures and mobility, and spine for rigidity, posture, flexibility, swallowing function, and muscle strength at each visit; EKG, Holter monitor, and echocardiography at least annually; additional cardiac surveillance as needed; pulmonary function tests every two to three years and annually in those with respiratory compromise; cholesterol panel with triglycerides, hemoglobin A1c, and blood glucose every two to three years or more frequently in those with abnormalities. Agents/circumstances to avoid: Triggering agents for malignant hyperthermia, such as depolarizing muscle relaxants (succinylcholine) and volatile anesthetic drugs (halothane, isoflurane); obesity. Evaluation of relatives at risk: Molecular genetic testing if the pathogenic variant(s) in the family are known; clinical evaluation, including musculoskeletal evaluation and cardiac assessment, if the pathogenic variant(s) in the family are not known. EDMD is inherited in an X-linked (XL), autosomal dominant (AD), or (rarely) autosomal recessive (AR) manner. XL-EDMD: If the mother of a proband has a pathogenic variant, the chance of transmitting it in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be heterozygous. Heterozygous females are usually asymptomatic but are at risk of developing cardiac disease, progressive muscular dystrophy (rare), and/or an EDMD phenotype (exceedingly rare). AD-EDMD: Sixty-five percent of individuals with LMNA-related AD-EDMD have a de novo pathogenic variant. Each child of an individual with AD-EDMD has a 50% chance of inheriting the pathogenic variant. AR-EDMD: If both parents are known to be heterozygous for a pathogenic variant associated with AR-EDMD, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants. Once the EDMD-related pathogenic variant(s) have been identified in an affected family member, prenatal and preimplantation genetic testing for EDMD are possible.
AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.
The aberrant expression of the toxic transcription factor DUX4 in skeletal muscle is a hallmark of facioscapulohumeral muscular dystrophy. Effective therapeutic strategies will likely require the inhibition of DUX4, with adeno-associated virus (AAV)-mediated therapies being among the promising approaches. However, the regenerative nature of muscle tissue can impact the long-term efficacy of AAV transduction, leading to reduced transgene persistence and diminishing the sustainability of gene inhibition over time. In this study, we utilized an AAV vector carrying a short hairpin RNA targeting DUX4 (shDUX4) to suppress DUX4 expression in the ACTA1-MCM; FLExDUX4/+ mouse model, which exhibits progressive muscular dystrophy. One month following AAV administration, the treatment significantly mitigated the DUX4-associated pathological features, including molecular, histopathological, and functional force-velocity-endurance (FoVE) parameters. However, by 10 months post-treatment, the therapeutic effects had substantially diminished, with most pathological markers remaining uncorrected and no sustained improvement in muscle force. This decline in therapeutic effect was associated with reduced DUX4 knockdown and a concurrent loss of AAV genomes. These findings highlight that although AAV-mediated gene therapy holds significant promise for FSHD treatment, challenges such as muscle fiber turnover and AAV genome dilution must be overcome to achieve sustained therapeutic benefit.
Incidence and health burden of 20 rare neurological diseases in South China from 2016 to 2022: a hospital-based observational study.
Rare neurological diseases (RNDs) result in severe health burdens worldwide. Data from China are limited. We aimed to investigate the health burden of 20 RNDs in Guangdong Province (GD), which contains two-thirds of the population of South China. The hospitalization data of 20 RNDs were described using hospital-based front sheet data from 3,037 hospitals of GD from 2016 to 2022. The 20 RNDs included amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth Disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, congenital myotonia, congenital myasthenic syndrome, Dravet syndrome, Fabry disease, hereditary spastic paraplegia, Huntington disease, Leber hereditary optic neuropathy, mitochondrial encephalopathy (ME), multi-focal motor neuropathy, myotonic dystrophy, primary hereditary dystonia, progressive muscular dystrophy (PMD), spinal and bulbar muscular atrophy, spinal muscular atrophy (SMA), spinocerebellar ataxia, Wilson disease (WD) and X-linked adrenoleukodystrophy. Age were presented as mean and standard deviation while length of hospital stay as median and interquartile range (25th and 75th percentiles). The other variables were described as number and percentage. The data were analyzed by Joinpoint regression. There were 9,351 cases, including 330 ICU and 155 death cases. The average age was 33.7 ± 22.0 y, and 63.8% of patients were male. From 2016 to 2022, the number of RND (and juvenile RND) cases were 1034 (184), 1174 (293), 1443 (374), 1422 (320), 1331 (337), 1432 (409) to 1515 (515). ICU (and juvenile ICU) cases rose from 28 (3), 34 (6), 24 (4), 38 (11), 46 (13), 54 (24) to 106 (56). Joinpoint regression showed significant upward trend in percentages of juvenile and juvenile ICU cases (APC = 8.13, P< 0.05; APC = 28.42, P< 0.05). The fop five RNDs were WD, ASL, PMD, ME, and SMA, which accounted for 79.7% of all, 99.1% of ICU, and 94.8% of death cases. We demonstrated that the increase in health burden of RNDs was mainly evident in juveniles in South China from 2016 to 2022. The top 5 RNDs accounted for majority of the critical patients.
Novel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.
The COL12A1 gene encodes Collagen XII α 1 chain, forming a biologically functional Collagen XII through a trimeric structure. Collagen XII dysfunction can lead to hereditary neuromuscular diseases with phenotypic profiles ranging from rare Ullrich congenital muscular dystrophy 2 (biallelic variant) to Bethlem myopathy 2 (uniallelic variant). Currently, only 29 COL12A1 deficiency cases have been reported, mainly featuring hypotonia, progressive muscular dystrophy, and skeletal deformities. Newborns cases were relatively rare. Here, we describe a neonate with hypotonia, weak spontaneous movement, convulsions, and respiratory failure at birth. Identification of a novel variant of COL12A1 by whole exome sequencing and Sanger sequencing, NM_004370.6: c.7622 C > T, p.Ser2541Phe. Molecular dynamics simulation revealed its location in the thrombospondin N-terminal domain, potentially destabilizing the Collagen XII trimer's structure. Our case report expands the COL12A1 genotype and phenotype spectrum, suggesting the presence of neonatal hypotonia and highlighting the importance of vigilance for respiratory clinical manifestations.
Publicações recentes
Gmppb-mutant mice exhibit dystroglycanopathy symptoms that are rescued with GSK3β inhibition or AAV-mediated GMPPB gene replacement.
A national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.
Emery-Dreifuss Muscular Dystrophy.
Clinical application of nanopore sequencing for haplotype linkage analysis in preimplantation genetic testing for Duchenne muscular dystrophy.
AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.
📚 EuropePMC1.104 artigos no totalmostrando 72
Muscle meets Lysosomes: emerging strategies in muscular dystrophy.
AutophagyA national biobank framework for rare diseases: Standardized infrastructure and cross-institutional collaboration accelerating translational innovation in China.
HGG advancesClinical application of nanopore sequencing for haplotype linkage analysis in preimplantation genetic testing for Duchenne muscular dystrophy.
Scientific reportsAAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.
Molecular therapy. Methods & clinical developmentObligatory and accessory respiratory muscle structure, function and control in early and advanced disease in the mdx mouse model of Duchenne muscular dystrophy.
The Journal of physiologyIncidence and health burden of 20 rare neurological diseases in South China from 2016 to 2022: a hospital-based observational study.
Orphanet journal of rare diseasesRetinopathy associated with facioscapulohumeral muscular dystrophy. A case report treated with intravitreal dexamethasone implant and laser photocoagulation.
Archivos de la Sociedad Espanola de OftalmologiaNovel variant of COL12A1 gene causing neonatal hypotonia and respiratory failure.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyAsymptomatic and oligosymptomatic states of dysferlinopathy.
Journal of neuromuscular diseasesImproving quality of life in palliative care: palatal lift prosthesis in a patient with periodontal disease.
BMJ case reportsCharacterization of Dystrophin Dp71 Expression and Interaction Partners in Embryonic Brain Development: Implications for Duchenne/Becker Muscular Dystrophy.
Molecular neurobiologyNeurexin facilitates glycosylation of Dystroglycan to sustain muscle architecture and function in Drosophila.
Communications biologyMolecular, Histological, and Functional Changes in Acta1-MCM;FLExDUX4/+ Mice.
International journal of molecular sciencesNovel Variant in ANO5 Muscular Dystrophy: Identification by Whole Genome Sequencing and Quad Analysis.
GenesUnveiling the Respiratory Muscle Strength in Duchenne Muscular Dystrophy: The Impact of Nutrition and Thoracic Deformities, Beyond Spirometry.
Children (Basel, Switzerland)Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.
Cold Spring Harbor perspectives in biologySubspecialty Health Care Utilization in Pediatric Patients With Muscular Dystrophy in the United States.
Neurology. Clinical practiceAppraising the Physical Activity Levels of Saudis with Physical Disabilities: Effects of Disability Type, Mobility Assistive Devices, and Demographic Factors.
Healthcare (Basel, Switzerland)[Searching for non-canonical functions of aminoacyl-tRNA synthases based on mutations carried by Charcot-Marie-Tooth patients].
Postepy biochemiiA DMD case caused by X chromosome rearrangement.
Yi chuan = HereditasArtificial Intelligence for Evaluation of Retinal Vasculopathy in Facioscapulohumeral Dystrophy Using OCT Angiography: A Case Series.
Diagnostics (Basel, Switzerland)Dystrophin (DMD) Missense Variant in Cats with Becker-Type Muscular Dystrophy.
International journal of molecular sciencesPrevalence Study of Duchene Muscular Dystrophy and its Genetic Sequence in Southern India.
Iranian journal of child neurologyA Longitudinal Follow-Up Study of Intellectual Function in Duchenne Muscular Dystrophy over Age: Is It Really Stable?
Journal of clinical medicineMinimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice.
Acta neuropathologica communicationsSystemic AAV9.BVES delivery ameliorates muscular dystrophy in a mouse model of LGMDR25.
Molecular therapy : the journal of the American Society of Gene TherapySurgical treatment for lumbar hyperlordosis associated with facioscapulohumeral muscular dystrophy: A case series.
Journal of orthopaedic science : official journal of the Japanese Orthopaedic AssociationHeterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy.
Nature communicationsRandomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Muscle & nerveCAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report.
OncoTargets and therapyThe good, the bad, and the utilitarian: attitudes towards genetic testing and implications for disability.
Current psychology (New Brunswick, N.J.)Efficacy and safety of glucocorticoids in the treatment of progressive muscular dystrophy in children: a systematic review and meta-analysis.
Translational pediatricsMicrohomology-Mediated Nonhomologous End Joining Caused Rearrangement of EMD and FLNA in Emery-Dreifuss Muscular Dystrophy.
Frontiers in geneticsPulmonary dysfunction in children with Duchenne muscular dystrophy may occur earlier than we thought - analysis using novel methodology based on z-scores.
Archives of medical science : AMSThe lncRNA 44s2 Study Applicability to the Design of 45-55 Exon Skipping Therapeutic Strategy for DMD.
Biomedicines[Professor LIN Guo-hua's experience in treatment of progressive muscular dystrophy with acupuncture].
Zhongguo zhen jiu = Chinese acupuncture & moxibustionPreclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.
Human gene therapyA novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic Dmd deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy.
Disease models & mechanismsOvine congenital progressive muscular dystrophy (OCPMD) is a model of TNNT1 congenital myopathy.
Acta neuropathologica communicationsLAMA2 Neuropathies: Human Findings and Pathomechanisms From Mouse Models.
Frontiers in molecular neuroscienceA novel SYNE2 mutation identified by whole exome sequencing in a Korean family with Emery-Dreifuss muscular dystrophy.
Clinica chimica acta; international journal of clinical chemistryRecurrent hypotension induced by sacubitril/valsartan in cardiomyopathy secondary to Duchenne muscular dystrophy: A case report.
World journal of clinical casesA newly discovered case of progressive muscular dystrophy caused by exon deletion mutation of Duchenne muscular dystrophy gene 12-28.
Journal of biological regulators and homeostatic agentsClinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
BMC neurologyChart validation of an algorithm for identifying hereditary progressive muscular dystrophy in healthcare claims.
BMC medical research methodology[Morphological characteristics of paravertebral muscles in patients with scoliosis caused by primaryprogressive muscular dystrophies].
Arkhiv patologiiProteomic identification of elevated saliva kallikrein levels in the mdx-4cv mouse model of Duchenne muscular dystrophy.
Biochemistry and biophysics reportsA novel pathogenic variant in TNPO3 in a Hungarian family with limb-girdle muscular dystrophy 1F.
European journal of medical geneticsSteroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report.
Neuromuscular disorders : NMDHuman Adipose-Derived CD146+ Stem Cells Increase Life Span of a Muscular Dystrophy Mouse Model More Efficiently than Mesenchymal Stromal Cells.
DNA and cell biologyA novel mutation in the DYSF gene in a patient with a presumed inflammatory myopathy.
Neuropathology : official journal of the Japanese Society of NeuropathologyEffects of Ovariectomy in an hSOD1-G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis (ALS).
Medical science monitor : international medical journal of experimental and clinical research[Clinical and genetic characteristics of facioscapulohumeral muscular dystrophy Landuzi-Dezherina type 1].
Zhurnal nevrologii i psikhiatrii imeni S.S. KorsakovaTreatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
Skeletal muscleA De novo Mutation in Dystrophin Causing Muscular Dystrophy in a Female Patient.
Chinese medical journalAtypical Lipomatous Tumor/Well-Differentiated Liposarcoma Developed in a Patient with Progressive Muscular Dystrophy: A Case Report and Review of the Literature.
Case reports in orthopedicsA Japanese male with a novel ANO5 mutation with minimal muscle weakness and muscle pain till his late fifties.
Neuromuscular disorders : NMDChildhood Activity on Progression in Limb Girdle Muscular Dystrophy 2I.
Journal of child neurologyγ-sarcoglycan and dystrophin mutation spectrum in an Algerian cohort.
Muscle & nerveDNAJB6 Myopathies: Focused Review on an Emerging and Expanding Group of Myopathies.
Frontiers in molecular biosciencesTransgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?
PloS oneWhole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C).
Case reports in geneticsA Case Report of an Infant with Robertsonian Translocation (15;22)(q10;q10) and Literature Review.
Annals of clinical and laboratory scienceFacioscapulohumeral dystrophy myoblasts efficiently repair moderate levels of oxidative DNA damage.
Histochemistry and cell biology[Diagnosis and natural history of Duchenne muscular dystrophy].
Archives de pediatrie : organe officiel de la Societe francaise de pediatrieGenetic characterization and improved genotyping of the dysferlin-deficient mouse strain Dysf (tm1Kcam).
Skeletal muscleMesoangioblast delivery of miniagrin ameliorates murine model of merosin-deficient congenital muscular dystrophy type 1A.
Skeletal musclePregnancy and delivery in Leyden-Möbius muscular dystrophy. Case Report.
Neuro endocrinology letters[Glucocorticoid therapy of progressive muscular dystrophy: the current state and progress].
Zhonghua er ke za zhi = Chinese journal of pediatricsMotor unit reorganization in progressive muscular dystrophies and congenital myopathies.
Neurologia i neurochirurgia polskaPlectin isoform P1b and P1d deficiencies differentially affect mitochondrial morphology and function in skeletal muscle.
Human molecular geneticsWhole Exome Sequencing Reveals DYSF, FKTN, and ISPD Mutations in Congenital Muscular Dystrophy Without Brain or Eye Involvement.
Journal of neuromuscular diseasesAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Distrofia muscular progressiva.
É de uma associação que acompanha esta doença? Fale com a gente →
Doença com base genética
Um médico geneticista pode ajudar no diagnóstico de Distrofia muscular progressiva e no aconselhamento genético da família.
Doenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Perguntas frequentes
O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu
É uma afecção do sistema neuromuscular catalogada sob o código ORPHA:206644 e identificador MONDO:0016106. Ela engloba alterações estruturais que provocam fraqueza muscular e substituição fibroadiposa do tecido muscular.
Referências
Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete
5 fontes citadas no texto · 8 publicações do grafo RarasNet (PubMed) · 5 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Citar este verbete
Raras. (2026). Distrofia muscular progressiva. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/distrofia-muscular-progressiva
Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
Distrofia muscular progressiva
📋 Origem dos dados
Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.
- Doença rara (ontologia)
- fonte: Orphanet
- Identificador unificado
- fonte: MONDO
- NIH/GARD
- fonte: GARD (NIH)
- Dado público estruturado
- fonte: Wikidata
- Moléculas estudadas na doença
- fonte: OpenTargets